What is Taro Pharmaceutical Industries EV-to-EBIT?
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Taro Pharmaceutical Industries's Enterprise Value is $738.9 Mil.
Taro Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $43.7 Mil. Therefore, Taro Pharmaceutical Industries's EV-to-EBIT for today is 16.90.
The historical rank and industry rank for Taro Pharmaceutical Industries's EV-to-EBIT or its related term are showing as below:
TARO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -74.59 Med: 7.55 Max: 39.52
Current: 16.9
During the past 13 years, the highest EV-to-EBIT of Taro Pharmaceutical Industries was 39.52. The lowest was -74.59. And the median was 7.55.
TARO's EV-to-EBIT is ranked better than 51.04% of 670
companies
in the Drug Manufacturers industry
Industry Median: 17.185
vs TARO: 16.90
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Taro Pharmaceutical Industries's Enterprise Value for the quarter that ended in Dec. 2023 was $668.1 Mil.
Taro Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $43.7 Mil. Taro Pharmaceutical Industries's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 6.55%.
Taro Pharmaceutical Industries EV-to-EBIT Historical Data
The historical data trend for Taro Pharmaceutical Industries's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Taro Pharmaceutical Industries's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taro Pharmaceutical Industries's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taro Pharmaceutical Industries's EV-to-EBIT falls into.
Taro Pharmaceutical Industries's current Enterprise Value is $738.9 Mil.
Taro Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taro Pharmaceutical Industries's Enterprise Value for the quarter that ended in Dec. 2023 was $668.1 Mil.
Taro Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taro Pharmaceutical Industries EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TARO has been successfully added to your 